Our Commitment
Fosun Pharma regards innovation as the most important social responsibility in sustainable corporate development. Focosing on unmet clinical needs, the company promotes the launch of more accessible and effective innovative products to benefit patients through continuous innovation. Additionally, we support public health capacity development in developing countries and strive to advance equitable access to healthcare worldwide.
Our Governance
· The Board is responsible for formulating strategies related to inclusive healthcare
· The ESG Committee under the Board is responsible for overseeing, guiding, and reviewing related matters for the Board's consideration
· The ESG Management Committee is responsible for evaluating and managing the opportunities and impacts that inclusive healthcare may bring to the Company, sets relevant goals, and reports regularly to the Board and the ESG Committee under the Board
· The ESG Working Group is responsible for advancing and implementing specific tasks and providing regular reports to the ESG Management Committee
· The ESG Committee under the Board is responsible for overseeing, guiding, and reviewing related matters for the Board's consideration
· The ESG Management Committee is responsible for evaluating and managing the opportunities and impacts that inclusive healthcare may bring to the Company, sets relevant goals, and reports regularly to the Board and the ESG Committee under the Board
· The ESG Working Group is responsible for advancing and implementing specific tasks and providing regular reports to the ESG Management Committee
-
In 2024, the Board of Directors held1meeting on inclusive healthcare topics
-
In 2024, the ESG Committee under the Board held2meetings regarding inclusive healthcare initiatives
Our Initiatives
- Enhancing the Accessibility and Affordability of Medicine
- Malaria Prevention and Treatment
- Supporting Healthcare Development in Developing Countries
- Focusing on R&D for Rare Diseases
- Fair Pricing
Our Achievements
-
RMB 5.554 billion
In 2024, we invested RMB 5.554 billion in R&D
We have obtained marketing approval for 7 innovator drugs/biosimilars, covering a total of 16 indications -
3
We have launched 3 rare disease drugs
with drugs for 9 indications for rare diseases currently under research -
over 80 million
Our artesunate for injection has helped treat over 80 million severe malaria patients worldwide
*As of December 31, 2024
